Skip to main content

Advertisement

SpringerLink
Log in

Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients

  • Nephrology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

An Erratum to this article was published on 18 November 2011

Abstract

Background

Advanced glycation end-products (AGE) accumulate in CKD and may predispose to cardiovascular disease by inducing inflammatory and oxidant stress in the vascular endothelium. Soluble forms of the receptor for AGE (RAGE) may be protective against these effects by binding AGE in the soluble phase. Accumulating evidence suggests a protective role of soluble RAGE against vascular calcification. This study investigates the association between endogenous soluble RAGE (esRAGE) and vascular calcification in hemodialysis patients.

Methods

We studied 65 non-diabetic hemodialysis patients, on 3 × 4 h dialysis schedule, and 19 controls. Serum levels of esRAGE, hsCRP, parathormone, lipids, calcium, and phosphorus were measured. Aortic calcification index (ACI) was measured using non-contrast CT of the abdominal aorta.

Results

Aortic calcification was detected in 64 out of 65 hemodialysis patients. Levels of esRAGE were lower in hemodialysis patients (278 pg/ml, SD 101.1) than in controls (443 ± 109 pg/ml; P = 0.001). ACI correlated negatively in stepwise multivariate analysis with esRAGE (P = 0.002) and positively with hsCRP (<0.0001), systolic blood pressure (P < 0.0001) and dialysis vintage (P = 0.05); R 2 = 0.65.

Conclusion

Levels of esRAGE were low among hemodialysis patients and correlated negatively with ACI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Adragão T, Pires A, Birne R et al (2009) A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant 24:997–1002

    Article  PubMed  Google Scholar 

  2. Okuno S, Ishimura E, Kitatani K et al (2007) Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49:417–425

    Article  PubMed  Google Scholar 

  3. London GM, Gue’rin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731–1740

    Article  PubMed  Google Scholar 

  4. Cannata-Andía JB, Rodríguez-García M, Carrillo-López N et al (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 17:267–273

    Article  Google Scholar 

  5. GoodmanW and London G (2004) (on behalf of the vascular calcification Work Group). Vascular calcification in chronic kidney disease. Am J Kid Dis. 43:572–9

  6. NasrAllah MM, El-Shehaby AR, Salem MM et al (2010) Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 25:2679–2685

    Article  PubMed  CAS  Google Scholar 

  7. Ketteler M (2005) Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 14(4):337–342

    Article  PubMed  Google Scholar 

  8. Jono S, Shioi A, Ikari Y, Nishizawa Y (2006) Vascular calcification in chronic kidney disease. J Bone Miner Metab 24(2):176–181

    Article  PubMed  Google Scholar 

  9. Nikolov I, Joki N, Drueke T et al (2006) Beyond phosphate—role of uraemic toxins in cardiovascular calcification. Nephrol Dial Transplant 21:3354–3357

    Article  PubMed  CAS  Google Scholar 

  10. Meerwaldt R, Zeebregts CJ, Navis G et al (2009) Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 53:138–150

    Article  PubMed  Google Scholar 

  11. Yan SF, Ramasamy R, Schmidt AM (2010) Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 79:1379–1386

    Article  PubMed  CAS  Google Scholar 

  12. Basta G, Leonardis D, Mallamaci F et al (2010) Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 77:225–231

    Article  PubMed  CAS  Google Scholar 

  13. Vazzana N, Santilli F, Cuccurullo C et al (2009) Soluble forms of RAGE in internal medicine. Intern Emerg Med 4:389–401

    Article  PubMed  Google Scholar 

  14. Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196:9–21

    Article  PubMed  CAS  Google Scholar 

  15. Katakami N, Matsuhisa M, Kaneto H et al (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204:288–292

    Article  PubMed  CAS  Google Scholar 

  16. Choi KM, Yoo HJ, Kim HY et al (2009) Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 132:96–101

    Article  PubMed  CAS  Google Scholar 

  17. Nishizawa Y, Koyama H (2008) Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease. J Ren Nutr 18:76–82

    Article  PubMed  Google Scholar 

  18. Koyama H, Yamamoto H, Nishizawa Y (2007) Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2:331–339

    PubMed  Google Scholar 

  19. Yamagishi S, Fujimori H, Yonekura H et al (1999) Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem Biophys Res Commun 258:353–357

    Article  PubMed  CAS  Google Scholar 

  20. Ren X, Shao H, Wei Q et al (2009) Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 37:847–854

    PubMed  CAS  Google Scholar 

  21. Sigrist M, Bungay P, Taal MW et al (2006) Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 21:707–714

    Article  PubMed  Google Scholar 

  22. Basta G, Corciu AI, Vianello A et al (2010) Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis. Atherosclerosis 210:614–618

    Article  PubMed  CAS  Google Scholar 

  23. Taniwaki H, Ishimura E, Tabata T et al (2005) Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 20:2472–2478

    Article  PubMed  Google Scholar 

  24. Kabaya T, Nitta K, Kimura H et al (1999) Increased aortic calcification index in hemodialysis patients. Nephron 81:354–355

    Article  PubMed  CAS  Google Scholar 

  25. Maillard-Lefebvre H, Boulanger E et al (2009) Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 48:1190–1196

    Article  Google Scholar 

  26. Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901

    Article  PubMed  CAS  Google Scholar 

  27. Heidland A, Sebekova K, Schinzel R (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38(Suppl 1):S100–S106

    Article  PubMed  CAS  Google Scholar 

  28. Hori O, Yan SD, Ogawa S et al (1996) The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant 11(Suppl 5):13–16

    Article  PubMed  CAS  Google Scholar 

  29. Nin JW, Ferreira I, Schalkwijk CG et al (2009) EURODIAB Prospective complications study group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective complications study. Diabetologia 52:705–714

    Article  PubMed  CAS  Google Scholar 

  30. McNair ED, Wells CR, Mabood Qureshi A et al (2010) Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 341:135–138

    Article  PubMed  CAS  Google Scholar 

  31. Kalousová M, Hodková M, Kazderová M et al (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47:406–411

    Article  PubMed  Google Scholar 

  32. Jachymova M, Mestek O, Hodkova M et al (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026

    Article  PubMed  Google Scholar 

  33. Massy ZA, Maziere C, Kamel S et al (2005) Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr Nephrol 20:380–382

    Article  PubMed  CAS  Google Scholar 

  34. Moe SM, Chen NX (2004) Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95:560–567

    Article  PubMed  CAS  Google Scholar 

  35. Jean G, Bresson E, Terrat J et al (2009) Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 24:948–955

    Article  PubMed  CAS  Google Scholar 

  36. Katakami N, Matsuhisa M, Kaneto H et al (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204:288–292

    Article  PubMed  CAS  Google Scholar 

  37. Bellasi A, Raggi P (2007) Techniques and technologies to assess vascular calcification. Semin Dial 20:129–133

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank Prof. R Barsoum for his technical advice and critical review of our work and Dr. A Fathy for help with data gathering.

Conflict of interest

The authors have no conflict of interests to declare regarding the results of this study.

Author information

Authors and Affiliations

  1. Department of Nephrology, Kasr El-Aini School of Medicine, Cairo University, Cairo, Egypt

    Mohamed M. NasrAllah, Noha A. Osman & Usama A. A. Sharaf El Din

  2. Department of Medical Biochemistry, Kasr El-Aini School of Medicine, Cairo University, Cairo, Egypt

    Amal R. El-Shehaby

  3. Department of Endocrinology, Kasr El-Aini School of Medicine, Cairo University, Cairo, Egypt

    Mona M. Salem

  4. Department of Radiology, Kasr El-Aini School of Medicine, Cairo University, Cairo, Egypt

    Amr Nassef

  5. Department of Nephrology, Kasr El-Aini School of Medicine, Cairo University and International Kidney Centre, Cairo, Egypt

    Usama A. A. Sharaf El Din

Authors
  1. Mohamed M. NasrAllah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amal R. El-Shehaby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noha A. Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mona M. Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amr Nassef
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Usama A. A. Sharaf El Din
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed M. NasrAllah.

Rights and permissions

Reprints and permissions

About this article

Cite this article

NasrAllah, M.M., El-Shehaby, A.R., Osman, N.A. et al. Endogenous soluble receptor of advanced glycation end-products (esRAGE) is negatively associated with vascular calcification in non-diabetic hemodialysis patients. Int Urol Nephrol 44, 1193–1199 (2012). https://doi.org/10.1007/s11255-011-0007-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-011-0007-x

Keywords

Search

Navigation